FOR RESEARCH USE ONLY - NOT FOR HUMAN CONSUMPTION.
A COA is not a marketing attachment. It is the batch record that lets a laboratory decide whether a peptide is suitable for controlled research work. The best peptide COA fields make identity, purity, quantity, and traceability auditable without asking the buyer to fill in missing information. A report that only states “99% purity” does not meet that standard.
For research buyers evaluating a lyophilized peptide vial, the practical question is simple: can the document connect this exact vial to a defined material, a defined analytical result, and a defined release decision? If the answer is unclear, the COA has limited value regardless of how polished it looks.
> Compliance Notice
>
> FOR RESEARCH USE ONLY - NOT FOR HUMAN CONSUMPTION. Research-grade peptide materials are supplied solely for laboratory, analytical, and educational research purposes. They are not intended for human or animal use, ingestion, administration, diagnostic use, or any other non-research application.
What separates a usable COA from a generic report
A certificate of analysis should work as a controlled quality document, not a broad product specification sheet. Product-level specifications explain what a supplier intends to provide. A batch COA documents what was actually tested and released for one lot.
That distinction matters when comparing suppliers. A generic PDF may state a target purity or molecular weight but omit the lot number, test date, chromatogram, instrument method, or analyst authorization. It cannot independently establish that the vial in hand was the material evaluated.
A stronger report includes the material name, internal catalog reference, batch or lot number, date of manufacture or testing, retest or expiration date where applicable, and the quantity or vial configuration. These basic fields establish chain-of-identity before analytical results are even considered.
1. Material identity and peptide definition
The first field to review is the analyte identity. The COA should state the full peptide name and, when applicable, the amino acid sequence or an unambiguous sequence reference. Short names alone can create ambiguity, particularly where similarly named analogs, salt forms, modified residues, or terminal modifications are available.
For a defined synthetic peptide, an identity section should generally include the expected molecular weight and the observed molecular weight from mass spectrometry. The reported mass should be consistent with the specified molecular form. A buyer should also confirm whether the molecular weight is stated for the free base, acetate, trifluoroacetate, or another counterion-associated form.
Mass spectrometry is an identity confirmation tool, not a stand-alone purity determination. It can show that the expected molecular species is present, but it does not by itself quantify closely related impurities, deletion sequences, or synthesis byproducts. That is why the best COAs pair mass data with chromatographic purity data.
2. Batch number, test date, and traceability
The lot number is one of the most important peptide COA fields because it ties every result to a specific production batch. It should appear on the report and align with the vial label or accompanying batch documentation. A certificate without a traceable lot number is not batch-specific verification.
Look for a clear test date and, where the supplier uses a defined stability program, a retest date. Do not treat a long dating period as proof of quality on its own. Storage conditions, container closure, transport conditions, and the assay method all affect what dating information can reasonably support.
The COA should also identify the issuing laboratory or quality unit. If third-party verification is represented, the report should identify the independent laboratory and preserve the original test details rather than restating a conclusion in supplier-created language. A vendor summary can be useful, but it is not a substitute for the underlying report.
Best peptide COA fields for purity review
Purity is often the first specification buyers compare, but the number is meaningful only when the method is visible. For peptide materials, reversed-phase HPLC or UPLC is commonly used to estimate chromatographic purity. A reported result such as “>99% HPLC” should be accompanied by enough context to determine what that statement measures.
At minimum, look for the method designation, detected wavelength, chromatographic conditions or a method reference, integration basis, and the result expressed as area percent if that is the reported metric. A chromatogram should show the main peak, retention time, and relevant peak profile. It should also be legible enough to assess whether minor peaks were present and how they were integrated.
Chromatographic area purity is not the same as peptide content by mass. It indicates the relative signal distribution under a specified method. A batch may show high HPLC area purity while the actual peptide content is influenced by water, residual solvent, counterions, or other non-chromophoric components. Laboratories planning quantitative work should distinguish purity from assay whenever the experimental design requires it.
HPLC chromatogram and integration details
A chromatogram is most useful when it is connected to the sample and method. Review the sample identifier, injection sequence or run reference, retention time, wavelength, and integration report. A single cropped trace with no axes, no method reference, and no batch identifier provides less confidence than a complete analytical record.
The question is not whether every report uses identical formatting. Different qualified laboratories use different instruments and templates. The question is whether the report allows a technically informed reviewer to understand how the stated result was generated.
For high-purity research material, a primary peak consistent with the stated sequence and an HPLC result at or above the supplier’s release specification are expected quality signals. A supplier that states a 99% purity standard should provide batch evidence that supports that claim rather than relying on a catalog-level assertion.
Mass spectrometry results
A useful mass spectrometry field reports both calculated and observed molecular mass. Depending on the platform, the spectrum may display multiple charge states that deconvolute to the expected mass. The report should identify the technique, such as LC-MS or MALDI-TOF, and state the result in a way that can be compared with the expected peptide mass.
Minor mass differences require interpretation, not assumptions. They can arise from salt form, adducts, oxidation, incomplete deprotection, sequence-related variants, or reporting conventions. For that reason, observed mass should be reviewed alongside the sequence, specified form, and HPLC profile.
Fields that support quantitative laboratory planning
Not every research workflow needs the same depth of documentation. A qualitative screening project may prioritize identity and chromatographic purity. A protocol requiring accurate molar preparation may need additional information about peptide content, moisture, residual solvents, and counterion composition.
Where relevant, the COA or supporting quality package should state assay or net peptide content, water content by Karl Fischer or another validated approach, residual solvents, and elemental impurities. These fields are not decorative extras. They determine whether a weighed mass can be treated as peptide mass for quantitative calculations.
For example, a vial labeled with a nominal peptide amount and high HPLC purity may still require a content correction factor for precise molar work. That does not indicate a defective material. It reflects the difference between chromatographic purity and absolute analyte content.
A practical review may also include appearance, reconstitution-related handling information, storage conditions, and packaging configuration. These are supporting fields, not replacements for identity and purity testing. Avoid treating visual appearance or a supplier label as analytical evidence.
How to evaluate third-party verification
Third-party testing is valuable when it is independent, batch-specific, and method-transparent. The strongest documentation preserves the original laboratory report, identifies the sample or lot tested, and makes clear which tests were performed by the external laboratory versus the manufacturer.
Ask whether the third-party sample was drawn from the finished batch, whether the lot matches the item offered for sale, and whether the reported results include raw or reportable analytical outputs. A statement saying “third-party tested” without a corresponding batch record is a claim, not verification.
Peptide Source quality documentation should be assessed the same way as any research supplier’s documentation: by batch alignment, analytical method, stated acceptance criteria, and traceable release records. Controlled-facility production and fast US fulfillment support operational consistency, but they do not replace the analytical evidence on the COA.
A concise COA acceptance checklist
Before accepting a peptide lot for laboratory use, verify these four points:
- The product name, molecular form, quantity, and lot number match the vial and purchase record.
- The expected and observed molecular weights are reported and consistent with the stated peptide identity.
- The HPLC or UPLC purity result includes a method reference and a readable batch-specific chromatogram.
- The certificate identifies the testing party, test date, release authorization, and any relevant assay or content data.
Documentation should match the experiment
The best peptide COA is not necessarily the longest PDF. It is the one that answers the questions your protocol creates: What is this material? Which batch is it? How was identity confirmed? What does the purity result actually represent? Can the result be traced to an accountable laboratory?
FOR RESEARCH USE ONLY - NOT FOR HUMAN CONSUMPTION. Maintain the COA with the corresponding vial label, receiving record, and laboratory inventory entry. That small documentation habit makes later comparisons, repeat work, and batch investigations materially easier.
Prepared by the Research Team at The Peptide Source.